Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:MYOV Myovant Sciences (MYOV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Myovant Sciences Stock (NYSE:MYOV) 30 days 90 days 365 days Advanced Chart Ad DTIWhy buying gold might be a mistakeSomething strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Get Myovant Sciences alerts:Sign Up Key Stats Today's Range$26.98▼$27.0050-Day Range$26.88▼$26.9952-Week Range$7.67▼$27.06Volume2.26 million shsAverage Volume1.17 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Read More… Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Receive MYOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MYOV Stock News HeadlinesGlobal Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsightSeptember 25, 2024 | finance.yahoo.comThe Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | OpinionSeptember 12, 2024 | newsweek.comWith the “Bitcoin Loophole” you can help supercharge the gains by 10x or more!You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!November 10, 2024 | DTI (Ad)Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comGynecology Collaboration, R&D, and Licensing Deals Trends Report 2024May 7, 2024 | finance.yahoo.comWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline DrugsApril 18, 2024 | uk.finance.yahoo.com2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout YearJanuary 15, 2024 | forbes.comGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and RegionJanuary 11, 2024 | finance.yahoo.comSee More Headlines MYOV Stock Analysis - Frequently Asked Questions How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd. (NYSE:MYOV) issued its earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.11. The company earned $77.90 million during the quarter, compared to analysts' expectations of $72.67 million. When did Myovant Sciences IPO? Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings10/26/2021Today11/10/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webwww.myovant.com Phone442074003351FaxN/AEmployees407Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,980,000.00 Net Margins-48.47% Pretax Margin-42.81% Return on EquityN/A Return on Assets-39.36% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.45 Sales & Book Value Annual Sales$230.97 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-5.35Miscellaneous Outstanding Shares97,240,000Free Float95,388,000Market Cap$2.62 billion OptionableNot Optionable Beta2.17 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:MYOV) was last updated on 11/10/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredI Got FiredStarting off with a few hundred bucks, it wasn't long before I started generating $1,000 a day. Then $10,00...Opportunistic Trader | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
